Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

VIRAL INFECTION

Long-term control of HIV

Nature Reviews Microbiology volume 20, page 446 (2022)Cite this article

Subjects

Modern antiretroviral therapy (ART) is highly effective at suppressing human immunodeficiency virus (HIV) to undetectable levels, but suppression relies upon life-long adherence to medications. Issues with adherence, drug side effects and the evolution of ART resistance have prompted the development of alternative therapies aimed at suppressing HIV. Broadly neutralizing monoclonal antibodies (bNAbs) that target the HIV envelope glycoprotein (Env) offer a new approach for virological suppression. Regular infusions of two bNAbs (3BNC117 and 10-1074) can suppress viraemia, but the long-term feasibility of this approach is not well explored.

Your institute does not have access to this article

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

Buy

All prices are NET prices.

References

Original article

Download references

Author information

Authors and Affiliations

  1. Nature Reviews Microbiology http://www.nature.com/nrmicro/

    Ashley York

Authors
  1. Ashley York
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ashley York.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

York, A. Long-term control of HIV. Nat Rev Microbiol 20, 446 (2022). https://doi.org/10.1038/s41579-022-00759-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41579-022-00759-0

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing